Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
暂无分享,去创建一个
T. Aas | P. Lønning | A. Nysted | H. E. Fjösne | S. Lundgren | S. Knappskog | J. Lillehaug | R. Chrisanthar | E. Løkkevik | G. Anker | B. Østenstad | T. Risberg | I. Mjaaland | G. Skjonsberg | E. Schlichting